Haemodynamic profiles of children with end-stage heart failure

被引:28
|
作者
Chen, Sharon [1 ]
Dykes, John C. [1 ]
McElhinney, Doff B. [1 ]
Gajarski, Robert J. [2 ]
Shin, Andrew Y. [1 ]
Hollander, Seth A. [1 ]
Everitt, Melanie E. [3 ]
Price, Jack F. [4 ]
Thiagarajan, Ravi R. [5 ]
Kindel, Steven J. [6 ]
Rossano, Joseph W. [7 ]
Kaufman, Beth D. [1 ]
May, Lindsay J. [8 ]
Pruitt, Elizabeth [9 ]
Rosenthal, David N. [1 ]
Almond, Christopher S. [1 ]
机构
[1] Stanford Univ, 750 Welch Rd,Suite 305, Palo Alto, CA 94304 USA
[2] Nationwide Childrens Hosp, Columbus, OH USA
[3] Childrens Hosp Colorado, Aurora, CO USA
[4] Texas Childrens Hosp, Houston, TX 77030 USA
[5] Boston Childrens Hosp, Boston, MA USA
[6] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA
[7] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[8] Primary Childrens Med Ctr, Salt Lake City, UT USA
[9] Univ Alabama Birmingham, Pediat Heart Transplant Study Grp, Birmingham, AL USA
关键词
Paediatric heart failure; Haemodynamics; IN-HOSPITAL MORTALITY; MEDICAL-MANAGEMENT; VENOUS CONGESTION; FILLING PRESSURES; TRANSPLANTATION; OUTCOMES; THERAPY; ASSOCIATION; DIAGNOSIS; SOCIETY;
D O I
10.1093/eurheartj/ehx456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate associations between haemodynamic profiles and symptoms, end-organ function and outcome in children listed for heart transplantation. Methods and results Children <18 years listed for heart transplant between 1993 and 2013 with cardiac catheterization data [pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), and cardiac index (CI)] in the Pediatric Heart Transplant Study database were included. Outcomes were New York Heart Association (NYHA)/Ross classification, renal and hepatic dysfunction, and death or clinical deterioration while on waitlist. Among 1059 children analysed, median age was 6.9 years and 46% had dilated cardiomyopathy. Overall, 58% had congestion (PCWP>15mmHg), 28% had severe congestion (PCWP>22mmHg), and 22% low cardiac output (CI<2.2 L/min/m(2)). Twenty-one per cent met the primary outcome of death (9%) or clinical deterioration (12%). In multivariable analysis, worse NYHA/Ross classification was associated with increased PCWP [odds ratio (OR) 1.03, 95% confidence interval (95% CI) 1.01-1.07, P=0.01], renal dysfunction with increased RAP (OR 1.04, 95% CI 1.01-1.08, P=0.007), and hepatic dysfunction with both increased PCWP (OR 1.03, 95% CI 1.01-1.06, P < 0.001) and increased RAP (OR 1.09, 95% CI 1.06-1.12, P < 0.001). There were no associations with low output. Death or clinical deterioration was associated with severe congestion (OR 1.6, 95% CI 1.2-2.2, P=0.002), but not with CI alone. However, children with both low output and severe congestion were at highest risk (OR 1.9, 95% CI 1.1-3.5, P=0.03). Conclusion Congestion is more common than low cardiac output in children with end-stage heart failure and correlates with NYHA/Ross classification and end-organ dysfunction. Children with both congestion and low output have the highest risk of death or clinical deterioration.
引用
收藏
页码:2900 / 2909
页数:10
相关论文
共 50 条
  • [41] End-stage heart failure: quantity or quality of life?
    Delahaye, F
    Mercusot, A
    Carra, L
    Gouton, M
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2005, 98 (03): : 186 - 191
  • [42] Peritoneal ultrafiltration in end-stage congestive heart failure
    Wojtaszek, Ewa
    Malyszko, Jolanta
    Matuszkiewicz-Rowinska, Joanna
    CARDIOLOGY JOURNAL, 2014, 21 (02) : 115 - 120
  • [43] Mechanical circulatory support for end-stage heart failure
    Combes, Alain
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 69 : S30 - S35
  • [44] Body impedance studies in end-stage heart failure
    Stellato, D
    Cirillo, M
    De Santo, LS
    Maiello, C
    Marra, C
    De Vivo, F
    Anastasio, P
    Frangiosa, A
    Cirillo, G
    Cotrufo, M
    De Santo, NG
    Di Iorio, B
    MINERAL AND ELECTROLYTE METABOLISM, 1999, 25 (1-2) : 21 - 23
  • [45] PATHOPHYSIOLOGIC ASPECTS OF END-STAGE HEART-FAILURE
    FRANCIS, GS
    MCDONALD, K
    CHU, CX
    COHN, JN
    AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (03): : A11 - A16
  • [46] Assisted circulation for end-stage chronic heart failure
    Liotta, D
    ARTIFICIAL ORGANS, 1998, 22 (03) : 230 - 236
  • [47] Growth hormone in end-stage heart failure - Reply
    Giustina, A
    Volterrani, M
    Desenzani, P
    LANCET, 1997, 349 (9068): : 1843 - 1843
  • [48] Palliative care for end-stage heart failure.
    Goodlin S.J.
    Current Heart Failure Reports, 2005, 2 (3) : 155 - 160
  • [49] Chronic inotropic therapy in end-stage heart failure
    Hauptman, Paul J.
    Mikolajczak, Peter
    George, Anil
    Mohr, Clinton J.
    Hoover, Robert
    Swindle, Jason
    Schnitzler, Mark A.
    AMERICAN HEART JOURNAL, 2006, 152 (06) : 1096.e1 - 1096.e8
  • [50] Treatment of medically intractable end-stage heart failure
    Choi, Jin-Ho
    Jun, Eun Seok
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2008, 51 (04): : 306 - 316